Oova gives members longitudinal hormone insights across fertility and perimenopause, with data their clinicians can act on.
Clinically validated · FSA/HSA eligible · Developed at Mount Sinai
Fertility and perimenopause
One benefit, both populations.
Works with your vendors
Adds data to the stack you already have.
Low implementation lift
No network to build, no claims integration.
Clinically validated
Peer-reviewed, longitudinal hormone data.
Starts as a pilot
Scoped to a defined population.
Coverage becomes visible once a member enters clinical care. The months and years before that are invisible to the benefit system.
Trying
Tracking and guesswork. No objective data.
Uncertainty
Symptoms without answers. Self-funded.
Diagnosis
Specialist evaluation and workup.
Treatment
Medication, IUI, IVF, or hormone therapy.
The same gap runs longer in perimenopause, where coverage often starts at a prescription.
Two point solutions, one underlying problem: hormones that move over time, measured once or not at all.
Invisible today
Whether ovulation is happening, and when to stop trying and start asking.
What Oova adds
Quantitative hormone data across cycles, and a clinician-ready report for that first appointment.
Invisible today
Whether symptoms track a real hormone pattern, and whether therapy is working.
What Oova adds
Readings across weeks instead of one draw, so the trend behind the symptoms becomes visible.
Observed utilization
Journey length within the conception cohort
About this research: descriptive analysis of 49 Oova users, 2021–early 2026. All were included because they reported a pregnancy, so these figures describe journey length within that group, not conception rates generally. No control group or claims data; no causal or savings claims are made.
No blood draw, no lab visit. Results arrive as quantitative hormone values, not a smiley face.
A urine strip measuring estrogen, progesterone and LH together.
The phone camera returns real values, in plain language.
A HIPAA-compliant report she controls and brings to her own clinician.
Research partners
Not a care provider, and not a competitor to the vendor you already have. Oova supplies the measurement they lack.
Works alongside existing vendors
Members keep their current platform or clinician. Oova gives them better data.
Engages earlier in the journey
Reaches members before a benefit activates, where the out-of-pocket spend sits.
FSA and HSA eligible
Already reimbursable, so it can be introduced ahead of a full benefit decision.
Member-controlled data
HIPAA-compliant. Employers never receive individual hormone data.
Low implementation lift
No clinical network to stand up, no claims integration to begin.
Built on published science
Peer-reviewed work with Mount Sinai and academic partners, publicly listed.
We’re running employer pilots for fertility and perimenopause, scoped to a defined population.
For employers, brokers and benefits consultants, fertility benefit platforms, and women’s health partners.
Does this replace our fertility benefit?
No. It sits earlier than most fertility benefits reach, and works alongside whatever is already in place.
What data would our organization receive?
Aggregate, de-identified access and engagement reporting. Never individual hormone data.
Who is eligible?
A defined population agreed before launch, such as members trying to conceive or a target age band.
How is it priced?
Per member per cycle of monitoring, not per enrolled life, so cost tracks actual use.
Can you demonstrate cost savings?
Not yet, and we won’t claim otherwise. Testing cost effects is what the pilots are for.
How quickly can a pilot start?
No network to build and no claims integration needed, so timelines depend mainly on comms planning.